 2 3 Xammy Huu Nguyenla^{1,2}, Timothy A. Bates², Mila Trank-Greene², Mastura V 4 Fikadu G. Tafesse^{2†}, Marcel Curlin^{3†} 	
$\mathbf{A} = \mathbf{E}^{1} \mathbf{x} \mathbf{d} \mathbf{x} \mathbf{C} = \mathbf{T} \mathbf{e}^{2} \mathbf{f} \mathbf{M} \mathbf{e}^{2} \mathbf{f} \mathbf{C} \mathbf{v} \mathbf{r} \mathbf{f} \mathbf{r}^{3} \mathbf{f}$	
4 Fikadu G. Tafesse ² , Marcel Curlin ³	
5	
6 ¹ Department of Biomedical Engineering, Oregon Health and Science Univers	
7 USA. ² Department of Molecular Microbiology and Immunology, Oregon Hea	
8 University, Portland, OR, USA. ³ Division of Infectious Diseases, Oregon Hea	ulth and Science
9 University, Portland, OR, USA.	
10	
[†] Co-corresponding authors: Fikadu G. Tafesse, PhD, (503)-494-2635, <u>tafess</u>	
12 Marcel Curlin, MD, (503)-705-8952, <u>curlin@ob</u>	
133181 SW Sam Jackson Park Road, Portland, OF	R 97239
14	
15	
16	
17 The authors have declared that no conflicts of interest exist.	
18	
19	
20	
21 Abstract	
As novel SARS-CoV-2 variants continue to emerge, the updated XBB.1.5 mo	
remain to be evaluated in terms of immunogenicity against live clinical isolate	1
 boosting of IgG(2.1X), IgA(1.5X), and total IgG/A/M(1.7X) antibodies target receptor-binding domain and neutralizing titers against WA1(2.2X), XBB.1.50 	0 1

26 EG.5.1(10.5X), and JN.1(4.7X) variants.

27 Introduction

- 28 The updated monovalent COVID-19 vaccines containing the XBB.1.5 variant spike protein were
- recently approved, yet uptake has been hesitant¹. Clear evaluation of the immunogenicity of
- 30 variant-adapted vaccines is important to trust in future COVID-19 immunization campaigns,
- 31 especially with the emergence of neutralization-evading variants like JN.1. Studies have
- demonstrated induction of antibodies capable of neutralizing variant spike proteins $^{2-4}$; however,
- 33 such studies utilize pseudo-typed virus that recombinantly express variant spike proteins as
- opposed to true SARS-CoV-2. We evaluate the immunogenicity of XBB.1.5 vaccination in
- humans using live clinical isolates of SARS-CoV-2, which more fully captures the biology of
- 36 virus neutralization.
- 37

38 Methods

- Healthcare workers were recruited at Oregon Health & Science University (OHSU) between
- 40 October-November 2023. Paired serum samples were collected on the day of XBB.1.5
- 41 monovalent vaccine (Moderna) administration and ~21 days after vaccination. Anti-nucleocapsid
- 42 antibodies were detected by enzyme-linked immunosorbent assay (ELISA) to identify recent
- 43 infection. IgG, IgA, IgM, and total IgG/A/M antibody titers against the ancestral spike RBD
- 44 were determined by 50% ELISA effective concentrations (EC50). Live SARS-CoV-2
- 45 neutralizing antibody titers were determined by 50% focus reduction neutralization tests
- 46 (FRNT50) against ancestral SARS-CoV-2 (WA1) and variants (XBB.1.5, EG.5.1, and JN.1)
- 47 (Figure 1A). Reported p-values are the results of a restricted effect maximum likelihood model
- 48 or repeated measures ANOVA with Šídák's multiple comparisons tests. The OHSU Institutional
- 49 Review Board approved this study, and written informed consent was obtained from participants.
- 50 More details on laboratory and analysis methods can be found in the Supplemental Methods.

5152 **Results**

- 53 Fifty-five individuals enrolled (mean age, 53 years; 37 [67%] women). 11 (20%) of pre-boost
- samples and 15 (27%) of post-boost samples were positive for anti-nucleocapsid antibodies.
- 55 These samples were included in final analysis in order to report generalized boosting in a
- 56 population with heterogenous exposure history; however, removing these participants from
- analysis resulted in similar induction of antibodies by XBB.1.5 vaccination (Supplemental
- **Figure 1A-B**). As expected, the XBB.1.5 vaccine boosted total serum IgG/A/M antibodies
- targeting the spike RBD [post-boost GMT 293 (95% CI: 195-442) versus pre-boost GMT 174
- 60 (124-244); 1.7-fold change; p<0.0001]. IgG isotypes demonstrated a greater increase [post-boost
- 61 GMT 267 (196-363) versus pre-boost GMT 130 (95.7-176); 2.1-fold change; p<0.0001] than IgA
- 62 [post-boost GMT 96.1 (74.6-124) versus pre-boost GMT 62.8 (50.3-78.3); 1.5-fold change;
- p=.0002], possibly due to the intramuscular route of administration as opposed to mucosal
- vaccination. IgM isotypes trended toward a slight increase [post-boost GMT 76.6 (57.6-102)
- versus pre-boost GMT 57.1 (44.5-73.2); 1.3-fold change; p=.1548] likely due to their short-lived nature (**Figure 1B**). Importantly, the XBB.1.5 vaccine boosted neutralizing titers against the
- nature (Figure 1B). Importantly, the XBB.1.5 vaccine boosted neutralizing titers against the
 ancestral WA1 [post-boost GMT 11905 (8454-16766) versus pre-boost GMT 5518 (3899-7809);
- ancestrat wA1 [post-boost GW1 11905 (8454-10700) versus pre-boost GW1 5518 (8899-7809)
 2.1-fold change; p<0.0001] and the vaccine-matched XBB.1.5 variant [post-boost GMT 838
- 69 (548-1281) versus pre-boost GMT 114 (80.9-162); 7.4 fold-change; p<0.0001]. The vaccine also
- rouse results and results and
- pre-boost GMT 78.3 (55.0-112); 10.5 fold-change; p<.0001] and the currently dominant JN.1
- 72 (post-boost GMT 361 (270-483) versus pre-boost GMT 77.6 (60.7-99.2); 4.7 fold-change;

- p<.0001) (Figure 1C). To assess changes in the proportion of serum antibodies with neutralizing
- capacity, the serum neutralizing titer against a given variant was divided by the total IgG/A/M
- titer to produce a neutralizing potency index (NPI). The NPI against the ancestral WA1 strain
- 76 was unchanged by XBB.1.5 monovalent vaccination [post-boost GM 40.6 (25.8-63.9) versus
- pre-boost GM 31.8 (22.0-45.8); p=2931]. This is likely explained by pre-existing neutralizing
- immunity that is dominated by responses against WA1 epitopes due to prior COVID-19
- 79 vaccination with ancestral spike protein and/or historic infections by ancestral SARS-CoV-2
- strains. Importantly, the XBB.1.5 vaccine elicits an increase in NPI against XBB.1.5 [post-boost
- 81 GM 2.86 (1.72-4.76) versus pre-boost GM 0.658 (0.441-0.982); p<0.0001], EG.5.1 [post-boost GM 2.81 (1.62, 4.85) success based GM 0.451 (0.205, 0.680); p <0.0001], and IN 1 facet based
- 82 GM 2.81 (1.63-4.85) versus pre-boost GM 0.451 (0.295-0.689); p<0.0001], and JN.1 [post-boost GM 1.22 (0.781, 1.05) versus are based GM 0.447 (0.206, 0.652); p<0.0011 (Symplemental
- 83 GM 1.23 (0.781-1.95) versus pre-boost GM 0.447 (0.306-0.652); p<.0001] (**Supplemental**
- 84 Figure 1C).85

86 Discussion


- 87 Overall, these data provide direct evidence for the immunogenicity of the XBB.1.5 monovalent
- 88 vaccine against live clinical isolates of SARS-CoV-2. Neutralizing antibodies were boosted
- against the ancestral WA1 strain, the vaccine-matched XBB.1.5, and emergent EG.5.1 and JN.1,
- suggesting that updated vaccines may enhance protection against infection by historic and
- 91 vaccine-matched strains as well as novel, emerging variants. Furthermore, we demonstrate that
- 92 individuals have low ratios of antibodies capable of neutralizing XBB.1.5, EG.5.1, and JN.1
- prior to vaccination, and that the XBB.1.5 monovalent vaccine increases the capacity of serum
- antibodies to neutralize contemporary variants. IgG, IgA, and total IgG/A/M antibody titers were
- boosted, which likely includes expansion of a non-neutralizing compartment that mediates
- disease severity and longer-term protection through Fc effector functions⁵. Indeed, the XBB.1.5
- monovalent vaccine was reported to reduce risk of COVID-19 hospitalization by 76.1% in
 Denmark⁶. In the United States, analysis of two CDC vaccine effectiveness (VE) data networks
- Denmark⁶. In the United States, analysis of two CDC vaccine effectiveness (VE) data networks
 estimated 52% (95% CI: 47-57%) and 43% (27-56%) VE against hospitalization⁷. This study
- therefore supports public health recommendations to stay up to date with adapted COVID-19
- 101 vaccines.
- 102

103 Acknowledgements

- 104 The authors thank the many participants in this study for their generous contribution. We also
- 105 gratefully acknowledge the efforts of the entire OHSU COVID-19 serology study team. This
- 106 work was funded in part by NIH R01AI141549 (to FGT).

107 References

- 108 1. COVID-19 Vaccine Uptake and CDC's Commitment to Vaccine Equity | CDC. 109
 - https://www.cdc.gov/respiratory-viruses/whats-new/vaccine-equity.html (2023).
- 110 2. Stankov, M. V. et al. Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination. Lancet Infect. Dis. 24, e1-e3 (2024). 111
- 3. Patel, N. et al. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and 112 113 cellular immune responses against EG.5.1 and emerging XBB variants. Sci. Rep. 13, 19176 (2023). 114
- 4. Wang, O. et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing 115 116 antibodies against XBB subvariants and JN.1. Cell Host Microbe 32, 315-321.e3 (2024).
- 5. Chakraborty, S. et al. Early non-neutralizing, afucosylated antibody responses are associated 117 with COVID-19 severity. Sci. Transl. Med. 14, eabm7853 (2022). 118
- 119 6. Hansen, C. H. et al. Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine 120 against hospitalisation in Denmark: a national cohort study. Lancet Infect. Dis. 0, (2024).
- 7. DeCuir, J. Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 121
- Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters 122
- 123 and Hospitalization Among Immunocompetent Adults Aged ≥ 18 Years — VISION and IVY
- Networks, September 2023–January 2024. MMWR Morb. Mortal. Wkly. Rep. 73, (2024). 124
- 125




126


127 Figure 1. XBB.1.5 monovalent vaccination boosts spike RBD-binding isotypes and

neutralizing antibodies against live SARS-CoV-2. (a) Representative focus reduction
 neutralization test (FRNT) results showing wells infected with live SARS-CoV-2 after incubation

- 130 with serially diluted serum in duplicate, which were stained and counted to produce the
- 131 representative FRNT curve. (b) Serum antibody isotype titers against spike RBD were
- determined by ELISA and reported as EC50. (c) Live SARS-CoV-2 neutralization by serum
- antibodies was assessed by FRNT and reported as FRNT50s. The dotted lines indicate assay
- lower limits of detection. Geometric mean titers (GMT) for each bar were calculated in
- 135 GraphPad Prism. Boost ratios were calculated by dividing the post-XBB.1.5 vaccination GMT
- 136 (post) by pre-vaccination GMT (pre). Reported p-values are the result of a restricted effect
- 137 maximum likelihood model (b) or one-way repeated measures ANOVA (c) with Šídák's multiple
- comparisons tests (****, p<0.0001; ***, p<0.001; ns=not significant, p>0.05). All individual
- 139 data points are displayed as filled circles.
- 140



141



143 nucleocapsid seronegative participants and neutralization potency index (NPI) against

144 **contemporary variants in the overall cohort.** Participants with likely prior or current infection

145 (positive for anti-nucleocapsid antibodies) were excluded from analysis in (a-b). (a) Serum

- antibody isotype titers against spike RBD were determined by ELISA and reported as EC50. (b)
- Live SARS-CoV-2 neutralization by serum antibodies was assessed by FRNT and reported as
 FRNT50s. The dotted lines indicate assay lower limits of detection. Geometric mean titers
- FRNT50s. The dotted lines indicate assay lower limits of detection. Geometric mean titers
 (GMT) for each bar were calculated in GraphPad Prism. Boost ratios were calculated by dividing
- the post-XBB.1.5 vaccination GMT (post) by pre-vaccination GMT (pre). (c) NPIs for pre-
- 151 vaccination (pre) and post-vaccination (post) serum samples were calculated by dividing the
- 152 FRNT50 against the live SARS-CoV-2 variant by total IgG/A/M EC50 for a given participant.
- 153 The dotted line represents NPI = 1. Reported p-values are the result of restricted effect maximum
- 154 likelihood models (a,c) or one-way repeated measures ANOVA (b) with Šídák's multiple
- comparisons tests (****, p<0.0001; ***, p<0.001; ns=not significant, p>0.05). All individual
- 156 data points are displayed as filled circles.